Quintiles to buy BRI:
This article was originally published in Clinica
Quintiles, a leading contract research organisation, is to acquire BRI International in a stock swap valued at $127 million. BRI earlier this year merged with Medical Technology Consultants Europe to create a global medical device consultancy, MTC-BRI International (see Clinica No 695, p 16). Under the terms of the agreement, all of BRI's stock would be exchanged for 1.9 million shares of Quintiles stock, which closed on July 30th at $67.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.